Figure 3.
PFS in R/R CLL with acalabrutinib monotherapy for del(17p)/TP53m, uIGHV, CK overall, and CK without del(17p)/TP53m.

PFS in R/R CLL with acalabrutinib monotherapy for del(17p)/TP53m, uIGHV, CK overall, and CK without del(17p)/TP53m.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal